Flaherty, Hansen and Coffin of Colliers Meredith & Grew represent MIT in 15,000 s/f lease to Archemix Corp.

Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases, has executed a new 15,000 s/f lease to relocate its headquarters from 300 Third St. to 148 Sidney St. Archemix will occupy the entire building. Colliers Meredith & Grew's Joe Flaherty, Tucker Hansen and Ben Coffin represented the landlord, Massachusetts Institute of Technology (MIT), in the transaction. Ryan Weber of Thompson Hennessey & Partners represented Archemix. Specifics of the lease transaction were not disclosed. Built in 1920, and most recently renovated in 2003,148 Sidney St. is a single-story, fully integrated laboratory facility located one block south of University Park at MIT. Archemix is a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics. Using Archemix's processes for discovering aptamers, which are protected by its broad patent portfolio, Archemix is developing aptamer product candidates for rare hematological diseases. In addition, Archemix has licensed its intellectual property to third parties to develop their own aptamer product candidates in other areas. Currently, Archemix's licensees are evaluating five different aptamer product candidates in human clinical trials; two in Phase 2 and three in Phase 1. Archemix has additional partnerships with several pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck Serono, Pfizer, Takeda, Eli Lilly and Isis Pharmaceuticals. Aptamers are short, synthetically derived, oligonucleotides that form three-dimensional structures that bind with high specificity and affinity to protein and non-protein targets. As therapeutic agents, aptamers combine the optimal characteristics of both small molecule drugs and biologics without many of the associated disadvantages. Leveraging these unique attributes, Archemix is creating a new paradigm in drug discovery and development. Colliers Meredith & Grew is a Boston-based commercial real estate company with integrated service groups including brokerage, capital markets, counseling & valuation, development & advisory, investment sales, and property & asset management. In addition to representing its core clients in New England, Colliers Meredith & Grew provides national and international real estate services to its multi-market clients through Colliers International, a global leader in real estate services with more than 15,000 professionals operating out of 480 offices in 61 countries. The Lipsey Company and National Real Estate Investor magazine ranked Colliers International as the world's number two commercial real estate brand.